ProMIS Neurosciences Inc. (PMN)

In the past six months, ProMIS Neurosciences' stock price has been impacted by several events. A private placement financing of up to $175 million was announced on January 30, 2026, leading to a 24% stock price surge, and officially closed on February 3, 2026. A 1-for-25 reverse stock split was completed on November 28, 2025, and the company regained compliance with Nasdaq's minimum bid price rule on December 16, 2025. An earnings report was released on November 11, 2025. Between January 31, 2025, and January 30, 2026, the share price declined by 37.24%. A sell signal was issued on February 3, 2026, and the stock has since fallen by 19.94%.

ProMIS Neurosciences, Inc. does not typically experience demand seasonality. The demand for its products and services is primarily driven by the progress of its clinical trials, regulatory milestones, and the ongoing need for effective treatments for the diseases it targets.

ProMIS Neurosciences, Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody therapeutics for neurodegenerative diseases, including Alzheimer's, ALS, MSA, FTD, and Parkinson's. The company's product candidates include PMN310 for Alzheimer's disease, PMN267 for ALS, and PMN442 for MSA. ProMIS Neurosciences utilizes its proprietary thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates, along with its EpiSelect™ target discovery engine, to predict novel Disease Specific Epitopes (DSEs) on misfolded proteins.

ProMIS Neurosciences, Inc. has headquarters in Toronto, Ontario, Canada, and offices in Cambridge, Massachusetts, USA.

ProMIS Neurosciences has experienced positive developments impacting its brand reputation in the past year. The FDA granted Fast Track designation to PMN310 for Alzheimer's disease treatment. The company announced it had exceeded target enrollment in its PRECISE-AD Phase 1b clinical trial for PMN310 in Alzheimer's disease. New peer-reviewed publications highlighted the selective targeting of toxic oligomers and demonstrated plasma pTau as a predictive early endpoint in Alzheimer's trials.

ProMIS Neurosciences, Inc. has a diverse ownership structure. Major institutional owners include UBS Group AG, Disciplined Equity Management, Inc., and TD Waterhouse Canada Inc. Institutional investors collectively own 50.13% of the company's stock. A large shareholder group led by Fan Yu increased its beneficial ownership to 17.0% following the February 3, 2026, offering. Individual insiders, such as Neil Cashman and Max Milbury, have also made recent purchases.